Nanobiotix Shares Confirm Their Rebound with a +625% Yearly Increase
The French biotech continues its recovery in late afternoon trading, in a Parisian market distinctly on the rise. The stock continues to widen the gap with its 200-day moving average, while remaining distant from its mid-May record. Its annual performance remains exceptionally high.
A Rebound that Consolidates Recovery Above Short-Term Moving Averages
Nanobiotix shares are up 2.03% at €34.10 during the session, after closing at €33.42 the previous day. The stock has moved above its MM50 (€33.52, a gap of +1.73%) and is more firmly above the MM20 at €31.62. The MM200 remains far behind at €24.25, reflecting a gap of over 40% which mirrors the magnitude of the long-term rally (+625% over a year).
The RSI at 57 indicates a bullish momentum without excess, consistent with a positive MACD histogram at 0.44. Over three months, the stock has risen +31.76%, and nearly 11% over one month. The next resistance zone identified is at €35.18.
A Biotech Driven by Clinical Advances in a Favorable European Market
Today's rebound occurs in a supportive environment for European stocks, with the SBF 120 up by 0.67% and the CAC 40 advancing by 0.65%. The stock is among the leaders of the broad Paris index, alongside Sanofi (+1.67%) and Eurofins Scientific (+2.56%) in the health sector. Fundamentally, during the Q1 2026 release on June 2, the company highlighted the progress of clinical studies on JNJ-1900 (NBTXR3) and the strengthening of its Nanoprimer platform as development levers, while identifying as risks the limited progress in the current standard of care for inoperable non-small cell lung cancer and potential protocol analysis issues.
Dual listing in Paris (NANO) and on the Nasdaq (NBTX) allows direct arbitrage between the two markets, with a 1 for 1 ratio. In the short term, the resistance at €35.18 remains the next technical level to surpass to extend the movement.
